

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock Code: 1177)

**MAJOR TRANSACTION
DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement of Sino Biopharmaceutical Limited (the “**Company**”) dated 7 January 2016 in relation to the major transaction of the Company regarding the entering of the Subscription Agreement, pursuant to which the Company has conditionally agreed to subscribe for 1,907,845,112 new H Shares of China Cinda (the “**Announcement**”). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) further details of the Subscription Agreement and the transactions contemplated thereunder; (ii) other information as required to be disclosed under the Listing Rules; and (iii) the notice of the EGM and a form of proxy are expected to be despatched to the Shareholders on or before 28 January 2016. As additional time is required for the Company to prepare and finalise the contents of the Circular, the despatch date of the Circular will be postponed to a date on or before 18 February 2016.

By Order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairlady

Hong Kong, 28 January 2016

As at the date of this announcement, the Board comprises seven executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Mr. Xu Xiaoyang, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four independent non-executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.